Company Overview
BridgeBio Pharma, Inc. operates as a biopharmaceutical entity dedicated to discovering, developing, and delivering medicines specifically for patients suffering from genetic diseases. The company functions within the Healthcare sector and the Biotechnology industry, a segment characterized by high innovation potential but also significant regulatory and research risks. Its current scale is substantial, with a reported market capitalization of $13.58B, annual revenue of $502.08M, and an employee count of 834. The market cap figure of $13.58B, which significantly exceeds its trailing twelve-month revenue of $502.08M, indicates that the company is valued primarily on the future potential of its drug pipeline rather than current earnings performance. This valuation structure is typical for biotechnology firms where the primary asset is the intellectual property and clinical trial status of its treatments, such as Attruby, a next-generation oral small molecule near-complete TTR stabilizer. The disparity between the massive market capitalization and the relatively modest revenue stream highlights the speculative nature of the asset class, where investor confidence rests entirely on the successful commercialization of future products.
Financial Health
The company reported a revenue of $502.08M for the trailing twelve months, yet simultaneously posted a net income of $-724,931,008 and an EBITDA of $-496,630,016. The substantial gap between the positive revenue of $502.08M and the negative net income reveals a cost structure dominated by heavy research and development expenditures that far outweigh current sales proceeds. Free cash flow stands at $-325,290,624, indicating that the company is burning cash to fund its operations and development programs, which limits immediate financial flexibility and necessitates ongoing capital raising or asset monetization. Analysis of the three key margins shows a gross margin of 95.8%, suggesting highly efficient production costs relative to sales, contrasted sharply by an operating margin of -83.3% and a profit margin of -144.4%, which reflect the intense expense burden inherent in the early stages of drug development. The company holds $587.48M in cash against total debt of $1.86B, creating a net debt position, and the debt-to-equity ratio is listed as N/A, reflecting the absence of traditional equity metrics in this negative earnings environment. The current ratio of 2.77 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities more than two and a half times over. Return on Equity is N/A due to the negative equity position, while Return on Assets stands at -33.8%, revealing that management is currently utilizing the asset base to generate losses rather than profits.
Valuation Assessment
The trailing P/E ratio is N/A because the company has not generated positive earnings over the trailing twelve months, while the forward P/E is listed at 35035.00, a figure that implies market expectations for significant future earnings growth to justify the current stock price. The price-to-book ratio is -6.54, a negative metric that indicates the market values the company at a fraction of its book value or below, suggesting a high degree of risk or a lack of tangible asset backing relative to the share price. The price-to-sales ratio of 27.06 and the EV/EBITDA of -29.94 serve as alternative valuation metrics that suggest the company is priced at a steep premium to its sales volume and is currently trading with negative enterprise value relative to earnings. The 52-week high is $84.94 and the 52-week low is $28.32, providing a range within which the stock has traded over the past year. Based on the provided data, the exact current trading price is not explicitly stated to calculate the precise percentage deviation from the high or low, but the wide range of $56.62 between the high and low demonstrates significant intrayear volatility. The beta value of 1.18 indicates that the stock price is expected to be 18% more volatile than the broader market index, reflecting the heightened risk associated with small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year is reported at an extraordinary 2521.2%, while earnings growth is N/A due to the company's persistent net losses. The massive revenue growth figure suggests a recent expansion in sales or a change in accounting recognition, whereas the lack of earnings growth is expected given the negative net income and the fact that earnings cannot grow from a negative baseline without reaching profitability. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, instead choosing to retain all generated cash to reinvest into research, development, and operational scaling. This reinvestment strategy is standard for biotechnology firms in the development phase, where capital is required to advance clinical trials and secure regulatory approval for new therapies. The overall growth and income profile is defined by rapid top-line expansion coupled with negative earnings and no dividend distribution, presenting a high-risk, high-reward capital allocation scenario dependent on future product approvals. The absence of a dividend yield of 0.0% and a payout ratio of 0.0% further confirms that the company's financial model prioritizes long-term asset building over shareholder income distributions.